Dihydroergotamine ameliorates liver fibrosis by targeting transforming growth factor β type II receptor

Figure 5 Dihydroergotamine decreased the inflammatory infiltration of macrophages and extracellular matrix deposition in the liver. A and B: The flow cytometric analysis of CD11b⁺ cells (n = 6-8); C: The effects of dihydroergotamine (DHE) treatment on the mRNA expression levels of inflammation-related genes (n = 6-8); D: The effects of DHE treatment on the mRNA expression levels of extracellular matrix-related genes (n = 6-8); E: The protein levels of p-SMAD3 and α-SMA in liver tissues of mice in each group were detected by western blot (n = 3). All data are presented as means ± standard error of the mean. One-way ANOVA test was performed. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, and ^dP < 0.0001. TGFβ: Transforming growth factor β; TGFβR: Transforming growth factor β receptor; DHE: Dihydroergotamine.